Protara Therapeutics Holds Annual Stockholders Meeting

Protara Therapeutics ( (TARA) ) has issued an update.

On June 11, 2025, Protara Therapeutics held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and operational strategies. Stockholders elected three Class II directors to serve until 2028, ratified Ernst and Young LLP as the independent auditor for 2025, approved executive compensation, and amended the 2024 Equity Incentive Plan. These decisions reflect the company’s ongoing efforts to strengthen its leadership and financial oversight, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (TARA) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.

Spark’s Take on TARA Stock

According to Spark, TipRanks’ AI Analyst, TARA is a Underperform.

Protara Therapeutics faces considerable challenges typical in early-stage biotech, such as no revenue and persistent cash outflows. However, the strong equity and low debt levels provide some stability. The recent positive trial results are promising, but the stock remains high-risk due to its financial and operational metrics.

To see Spark’s full report on TARA stock, click here.

More about Protara Therapeutics

Protara Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for rare and specialty diseases. The company is dedicated to advancing innovative therapies to address unmet medical needs.

Average Trading Volume: 354,675

Technical Sentiment Signal: Sell

Current Market Cap: $130M

For detailed information about TARA stock, go to TipRanks’ Stock Analysis page.